Page 3 - Sight Biologic News Today

Neurology journal BRAIN publishes efficacy and safety results at 1.5-year post treatment BMJ1 Open Ophthalmology publishes characteristics of the ND4-LHON study population before treatment Regulatory

The credit facility will enable GenSight to support the development of its pipeline and in particular the preparation of the marketing of LUMEVOQ in Europe The credit facility consists of

EMA D120 Responses submitted in October as planned Two successful engineering batches of LUMEVOQ validate actions taken to correct low yields in previous runs €13.9 million of cash

Philippe Motté as Senior VP, Regulatory and QualityMichiel Hemels as VP, Global Pricing and Market AccessPARIS--(BUSINESS WIRE)--Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for reti...

Ramp up of sales marketing actions and investments to drive commercial launch of LUMEVOQ in Europe in 2023 Cash runway confirmed to early Q1 2023 Advanced discussions on refinancing

Study is first of its kind to explore the impact of LHON on patients and their relatives in four different countries Study determined that the impact of LHON extends beyond vision-related

Sustained demand of LUMEVOQ ATUs in France generating €3.1 million revenues in Q1 2022 €36.0 million of cash as of March 31, 2022; runway confirmed to early Q1 2023 Regulatory News: GenSight

New submission date for Day 120 responses: October 2022 Restart of validation batches in Q3 2022 Committee for Medicinal Products for Human Use (CHMP) opinion expected by Q3 2023 Regulatory

Light can be used to stimulate light-sensitive receptors in order to turn brain cells “on” and “off” at the flip of a switch,...

PARIS--(BUSINESS WIRE)--Dec 14, 2021--